Logo

American Heart Association

  18
  0


Final ID: Mo3006

Pulsed Field Ablation for the Treatment of Octogenarians with Atrial Fibrillation

Abstract Body (Do not enter title and authors here): Background
Pulsed field ablation (PFA) for atrial fibrillation (AF) has demonstrated comparable treatment efficacy with conventional thermal ablation. Despite its high safety profile and increasing adoption worldwide, little is known about the real-world data on the efficacy and safety of PFA in elderly AF patients.

Methods
We conducted a retrospective observational study of patients with AF who underwent PFA with a pentaspline catheter (Farapulse, Boston Scientific). Patients were categorized into two groups: <80 years and ≥80 years, and baseline characteristics, procedural data, and recurrence of atrial arrhythmia were compared.

Results
Among the 483 AF patients enrolled in the study (mean age 69±11, male 66%), 76 (16%) patients were ≥80 years of age. The octogenarian group was characterized by proportionally more females, lower body mass index, and a higher prevalence of vascular disease and chronic kidney disease, with significantly higher CHA2DS2-VASc scores compared to the younger group (P<0.001). Compared to the younger patients, more octogenarians underwent adjunctive posterior wall (71% vs. 50%, P<0.001) and anterior wall (26% vs. 12%, P =0.002) ablation. Procedure time, ablation catheter dwell time, and fluoroscopy times were comparable between the two age groups. There were zero complications in the octogenarian group and 9 (2.2%) complications in the younger group (P=0.19). Early follow-up data (128±100 days) showed comparable rates of atrial arrhythmia recurrence between the octogenarian and younger patient groups.

Conclusions
PFA demonstrates acceptable efficacy and excellent safety in elderly patients aged ≥80 years despite a higher burden of comorbidities.
  • Miyama, Hiroshi  ( WEILL CORNELL MEDICAL COLLEGE , New York , New York , United States )
  • Liu, Christopher  ( WEILL CORNELL MEDICAL COLLEGE , New York , New York , United States )
  • Ip, James  ( WEILL CORNELL MEDICAL COLLEGE , New York , New York , United States )
  • Goljo, Elden  ( WEILL CORNELL MEDICAL COLLEGE , New York , New York , United States )
  • Lerman, Bruce  ( WEILL MED CORNELL UNIV , New York , New York , United States )
  • Cheung, Jim  ( WEILL CORNELL MEDICAL COLLEGE , New York , New York , United States )
  • Lam, Matthew  ( WEILL CORNELL MEDICAL COLLEGE , New York , New York , United States )
  • Mccoy, Sean  ( WEILL CORNELL MEDICAL COLLEGE , New York , New York , United States )
  • Parker, Melissa  ( WEILL CORNELL MEDICAL COLLEGE , New York , New York , United States )
  • Maizes, Danielle  ( WEILL CORNELL MEDICAL COLLEGE , New York , New York , United States )
  • Collins, Griffin  ( Weill Cornell Medicine , New York , New York , United States )
  • Perera, Ruwanthi  ( WEILL CORNELL MEDICAL COLLEGE , New York , New York , United States )
  • Markowitz, Steven  ( WEILL CORNELL MEDICAL COLLEGE , New York , New York , United States )
  • Thomas, George  ( WEILL CORNELL MEDICAL COLLEGE , New York , New York , United States )
  • Author Disclosures:
    Hiroshi Miyama: DO NOT have relevant financial relationships | Christopher Liu: DO NOT have relevant financial relationships | James Ip: DO have relevant financial relationships ; Consultant:Abbott:Active (exists now) ; Consultant:Milestone Pharmaceuticals:Active (exists now) ; Consultant:Boston Scientific:Active (exists now) ; Consultant:Biotronik:Active (exists now) ; Consultant:Medtronic:Active (exists now) ; Researcher:Abbott:Active (exists now) ; Advisor:Abbott:Active (exists now) | Elden Goljo: No Answer | Bruce Lerman: DO NOT have relevant financial relationships | Jim Cheung: DO have relevant financial relationships ; Consultant:Biosense:Past (completed) ; Consultant:Medtronic:Past (completed) | Matthew Lam: DO NOT have relevant financial relationships | Sean McCoy: DO NOT have relevant financial relationships | Melissa Parker: No Answer | Danielle Maizes: No Answer | Griffin Collins: No Answer | Ruwanthi Perera: No Answer | Steven Markowitz: DO have relevant financial relationships ; Consultant:Boston Scientific:Active (exists now) ; Other (please indicate in the box next to the company name):J Wiley (Editorial):Active (exists now) ; Consultant:Abbott Laboratories:Active (exists now) ; Consultant:Zoll Medical:Active (exists now) | George Thomas: DO NOT have relevant financial relationships
Meeting Info:

Scientific Sessions 2025

2025

New Orleans, Louisiana

Session Info:

Insights Gained in Pulsed Field Ablation for Atrial Arrhythmias

Monday, 11/10/2025 , 10:30AM - 11:30AM

Abstract Poster Board Session

More abstracts on this topic:
Complete Versus Incomplete Revascularization Strategy in Myocardial Infarction and Multivessel Coronary Artery Disease in ≥65-Year-Old Patients: A Meta-Analysis.

Banga Akshat, Rathore Sawai Singh, Mautong Hans, Sah Biki, Gurav Jaiprakash, Talaei Fahimeh, Farrukh Ameer, Bansal Vikas

A RETROSPECTIVE EVALUATION OF RESOURCE UTILIZATION AND OUTCOMES IN PATIENTS USING MOBILE ECG DEVICES FOLLOWING ABLATION FOR ATRIAL FIBRILLATION

Fairman Alix, Loh Alexander, Druml Lauren, Triplett Cynthia, Liu Taylor, Pursnani Seema

More abstracts from these authors:
Simplifying Cardiology Research Abstracts: Assessing ChatGPT's Readability and Comprehensibility for Non-Medical Audiences

Malkani Kabir, Kini Vinay, Zhang Ruina, Falk Zachary, Tawde Prianca, Hughes Ryan, Parker Melissa, Collins Griffin, Maizes Danielle, Zhao Alexander

Serum Metabolomics Adds Predictive Value to Clinical and Polygenic Risk Scores for Atrial Fibrillation: A UK Biobank study of >240,000 Patients

Purkayastha Subhanik, Park Joseph, Beyer Sebastian, Lerman Bruce, Lo James, Cheung Jim

You have to be authorized to contact abstract author. Please, Login
Not Available